We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+3.36%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$54.7M
AUM Growth
-$48.9M
Cap. Flow
-$18.7M
Cap. Flow %
-34.12%
Top 10 Hldgs %
82.31%
Holding
42
New
10
Increased
6
Reduced
2
Closed
16

Top Buys

Rank Stock Value
1
AMRI
Albany Molecular Research Inc
AMRI
+$1.84M
2
AZN icon
AstraZeneca
AZN
+$1.79M
3
PFE icon
Pfizer
PFE
+$1.51M
4
QLTI
QLT Inc
QLTI
+$1.37M
5
AORT icon
Artivion
AORT
+$1.29M

Top Sells

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$9.9M
2
AGN
Allergan plc
AGN
+$7.24M
3
TWM icon
ProShares UltraShort Russell2000
TWM
+$5.56M
4
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$2.41M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 82.99%
2 Miscellaneous 17.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRI
1
DELISTED
Albany Molecular Research Inc
AMRI
$9.74M 17.8%
598,200
+100,000
+20% +$1.84M
AZN icon
2
AstraZeneca
AZN
$255B
$7.04M 12.86%
100,000
+25,000
+33% +$1.79M
TEVA icon
3
Teva Pharmaceuticals
TEVA
$43.8B
$5.75M 10.51%
100,000
– –
DGX icon
4
Quest Diagnostics
DGX
$27B
$5.18M 9.46%
77,208
– –
PFE icon
5
Pfizer
PFE
$160B
$4.67M 8.54%
158,100
+52,700
+50% +$1.51M
TWM icon
6
ProShares UltraShort Russell2000
TWM
$44M
$3.96M 7.24%
5,000
-6,250
-56% -$5.56M
LGND icon
7
Ligand Pharmaceuticals
LGND
$5.67B
$2.66M 4.86%
80,150
– –
AORT icon
8
Artivion
AORT
$1.3B
$2.27M 4.14%
200,000
+125,000
+167% +$1.29M
AMRI
9
CALL
DELISTED
Albany Molecular Research Inc
AMRI
$1.95M 3.57%
+120,000
New +$2.2M
SRNE
10
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.82M 3.32%
180,479
-60,489
-25% -$306K
QLTI
11
DELISTED
QLT Inc
QLTI
$1.4M 2.57%
+350,000
New +$1.37M
ARIA
12
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.03M 1.88%
150,000
+50,000
+50% +$313K
CEMP
13
CALL
DELISTED
Cempra, Inc.
CEMP
$940K 1.72%
+40,000
New +$598K
RIGL icon
14
Rigel Pharmaceuticals
RIGL
$875M
$908K 1.66%
40,000
– –
CYTK icon
15
Cytokinetics
CYTK
$10.8B
$801K 1.46%
+100,000
New +$429K
ARIA
16
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$687K 1.26%
100,000
– –
QLTI
17
CALL
DELISTED
QLT Inc
QLTI
$602K 1.1%
+150,000
New +$586K
ALIM
18
DELISTED
Alimera Sciences
ALIM
$554K 1.01%
+6,667
New +$541K
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$510K 0.93%
952
+833
+700% +$375K
AMRN
20
CALL
Amarin Corp
AMRN
$299M
$490K 0.9%
+25,000
New +$520K
FCSC
21
DELISTED
Fibrocell Science Inc.
FCSC
$409K 0.75%
10,518
– –
POZN
22
CALL
DELISTED
POZEN INC
POZN
$400K 0.73%
+50,000
New +$429K
STML
23
DELISTED
Stemline Therapeutics, Inc.
STML
$281K 0.51%
16,464
– –
ALIM
24
CALL
DELISTED
Alimera Sciences
ALIM
$277K 0.51%
+3,333
New +$270K
IMNN icon
25
Imunon
IMNN
$9.03M
$233K 0.43%
37
– –
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q4 2014 Portfolio in Review

As of Q4 2014, Healthcare Value Capital held 42 positions worth $54.7M, down 47% from $104M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Healthcare Value Capital withdrew a net $18.7M in Q4 2014, closing 16 positions and reducing 2 holdings. Its most notable exit was ANI Pharmaceuticals, an estimated $9.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 54% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital opened a new position in QLT Inc worth $1.4M.

  • Healthcare Value Capital's largest Q4 2014 buy was QLT Inc: 350,000 shares worth $1.4M.
  • Healthcare Value Capital added most to Albany Molecular Research Inc in Q4 2014, an estimated $1.84M increase.
  • Healthcare Value Capital's biggest Q4 2014 reduction was ProShares UltraShort Russell2000, cutting an estimated $5.56M.
  • Healthcare Value Capital fully exited ANI Pharmaceuticals in Q4 2014, selling an estimated $9.9M.
  • Healthcare Value Capital's ten largest holdings make up 82% of its $54.7M portfolio in Q4 2014.
  • Healthcare Value Capital opened 10 new positions and closed 16 in Q4 2014.
  • Healthcare Value Capital's portfolio value fell 47% quarter-over-quarter to $54.7M.

Based on Healthcare Value Capital's 13F filing for Q4 2014, filed 13 Feb 2015.